By including those without established ASCVD, this guidance goes beyond the evidence from clinical trials of the cardiovascular benefit of SGLT2-inhibitors in which a majority of participants (57–85%) had established cardiovascular disease [2]. Here, SLC5A2 is linked to cardiovascular disorder.